Archives of Advances in Biosciences

[1] Lolli F, Pallotti F, Rossi A, Fortuna MC, Caro G, Lenzi A, Sansone A, Lombardo F. Androgenetic alopecia: a review. Endocrine. 2017 Jul;57(1):9-17. [PMID]

[2] Yip L, Zaloumis S, Irwin D, Severi G, Hopper J, Giles G, Harrap S, Sinclair R, Ellis J. Gene‐wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. British Journal of Dermatology. 2009 Aug 1;161(2):289-94. [PMID]

[3] Otberg N, Finner AM, Shapiro J. Androgenetic alopecia. Endocrinology and metabolism clinics of North America. 2007 Jun 1;36(2):379-98. [PMID]

[4] Almohanna HM, Perper M, Tosti A. Safety concerns when using novel medications to treat alopecia. Expert opinion on drug safety. 2018 Nov 2;17(11):1115-28.. [PMID]

[5] Erratum. Expert Opinion on Emerging Drugs. 2015 Apr 3;20(2):347–347. [PMID]

[6] Vañó-Galván S, Camacho F. Novedades terapéuticas en tricología. Actas Dermo-Sifiliográficas. 2017 Apr 1;108(3):221-8.[PMID]

[7] Bienenfeld A, Azarchi S, Sicco KL, Marchbein S, Shapiro J, Nagler AR. Androgens in women: Androgen-mediated skin disease and patient evaluation. Journal of the American Academy of Dermatology. 2019 Jun 1;80(6):1497-506.[PMID]

[8] Sadick NS, Callender VD, Kircik LH, Kogan S. New insight into the pathophysiology of hair loss trigger a paradigm shift in the treatment approach. J Drugs Dermatol. 2017 Nov 1;16(11):s135-40. [PMID]

[9] Paus R, Cotsarelis G. The biology of hair follicles. New England journal of medicine. 1999 Aug 12;341(7):491-7.[PMID]

[10] Hardy MH. The secret life of the hair follicle. Trends in Genetics. 1992 Feb 1;8(2):55-61.[LINK]

[11] Hoover E, Alhajj M, Flores JL. Physiology, hair.[PMCID]

[12] Park AM, Khan S, Rawnsley J. Hair Biology: Growth and Pigmentation. Facial Plastic Surgery Clinics of North America. 2018 Aug 16;26(4):415-24. [PMID]

[13] Natarelli N, Gahoonia N, Sivamani RK. Integrative and mechanistic approach to the hair growth cycle and hair loss. Journal of clinical medicine. 2023 Jan;12(3):893.[PMID]

[14] Stenn KS, Paus R. Controls of hair follicle cycling. Physiological reviews. 2001.[PMID]

[15] Grymowicz M, Rudnicka E, Podfigurna A, Napierala P, Smolarczyk R, Smolarczyk K, Meczekalski B. Hormonal effects on hair follicles. International journal of molecular sciences. 2020 Jan;21(15):5342. [PMID]

[16] Ohnemus U, Uenalan M, Inzunza J, Gustafsson JA, Paus R. The hair follicle as an estrogen target and source. Endocrine reviews. 2006 Oct 1;27(6):677-706.[PMID]

[17] Truong AT, Duez C, Belayew A, Renard A, Pictet R, Bell GI, Martial JA. Isolation and characterization of the human prolactin gene. The EMBO journal. 1984 Feb 1;3(2):429-37.[PMID]

[18] Martinet L, Allain D, Weiner C. Role of prolactin in the photoperiodic control of moulting in the mink (Mustela vison). Journal of Endocrinology. 1984 Oct 1;103(1):9-15. [PMID]

[19] Bodó E, Kromminga A, Bíró T, Borbíró I, Gáspár E, Zmijewski MA, Van Beek N, Langbein L, Slominski AT, Paus R. Human female hair follicles are a direct, nonclassical target for thyroid-stimulating hormone. Journal of investigative dermatology. 2009 May 1;129(5):1126-39.[PMID]

[20] Slominski A, Tobin DJ, Zmijewski MA, Wortsman J, Paus R. Melatonin in the skin: synthesis, metabolism and functions. Trends in Endocrinology & Metabolism. 2008 Jan 1;19(1):17-24.[PMID]

[21] Janjetovic Z, Jarrett SG, Lee EF, Duprey C, Reiter RJ, Slominski AT. Melatonin and its metabolites protect human melanocytes against UVB-induced damage: Involvement of NRF2-mediated pathways. Scientific reports. 2017 Apr 28;7(1):1274.[PMID]

[22] Xiang L, Sunesara I, Rehm KE, Marshall Jr GD. Hair cortisol concentrations are associated with hair growth rate. Neuroimmunomodulation. 2017 May 12;23(5-6):287-94. [PMID]

[23] Stoehr JR, Choi JN, Colavincenzo M, Vanderweil S. Off-label use of topical minoxidil in alopecia: a review. American journal of clinical dermatology. 2019 Apr 1;20(2):237-50.[PMID]

[24] Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Minoxidil use in dermatology, side effects and recent patents. Recent patents on inflammation & allergy drug discovery. 2012 May 1;6(2):130-6.[PMID]

[25] Fiedler-Weiss VC. Minoxidil. Dermatol Clin. 1987 Jul;5(3):627–35. [PMID]

[26] Rumsfield JA, West DP, Fiedler-Weiss VC. Topical minoxidil therapy for hair regrowth. Clinical pharmacy. 1987 May 1;6(5):386-92.[PMID]

[27] Katz HI. Topical minoxidil: review of efficacy and safety. Cutis. 1989 Jan;43(1):94-8..[PMID]

[28] Kvedar JC, Baden HP. Topical minoxidil in the treatment of male pattern alopecia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 1987 Nov 12;7(6):191-7. [PMID]

[29] Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, Trancik RJ. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology. 2002 Sep 1;47(3):377-85.[PMID]

[30] Ghonemy S, Alarawi A, Bessar H. Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. Journal of Dermatological Treatment. 2021 Feb 17;32(2):236-41.[PMID]

[31] Chandran NS, Oranje AP. Minoxidil 5% solution for topical treatment of loose anagen hair syndrome. Pediatric dermatology. 2014 May;31(3):389-90. [PMID]

[32] Panchaprateep R. Medical treatment for androgenetic alopecia. Facial Plastic Surgery. 2024 Apr;40(02):252-66.[PMID]

[33] Headington JT. Hair follicle biology and topical minoxidil: possible mechanisms of action. Dermatologica. 1987 Jan 1;175(Suppl 2):19-22. [PMID]

[34] Friedman ES, Friedman PM, Cohen DE, Washenik K. Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. Journal of the American Academy of Dermatology. 2002 Feb 1;46(2):309-12.[PMID]

[35] Badreddine H. Pustular dermatosis of the scalp due to topical minoxidil 5%. The Pan African Medical Journal. 2018;30.[PMID]

[36] Kiratiwongwan R, Boonchai W, Kanokrungsee S. Allergic contact dermatitis to topical preparations containing minoxidil: a systematic review and individual participant data meta-analysis. Dermatitis®. 2025 May 1;36(3):200-6.[PMID]

[37] Hagemann T, Schlütter‐Böhmer B, Allam JP, Bieber T, Novak N. Positive lymphocyte transformation test in a patient with allergic contact dermatitis of the scalp after short‐term use of topical minoxidil solution. Contact Dermatitis. 2005 Jul;53(1):53-5.[PMID]

[38] Claudet I, Cortey C, Honorat R, Franchitto N. Minoxidil topical solution: an unsafe product for children. Pediatric Emergency Care. 2015 Jan 1;31(1):44-6. [PMID]

[39] Jordan TJ, Yaxley PE, Culler CA, Balakrishnan A. Successful management of minoxidil toxicosis in a dog. Journal of the American Veterinary Medical Association. 2018 Jan 15;252(2):222-6.[PMID]

[40] McClellan KJ, Markham A. Finasteride: a review of its use in male pattern hair loss. Drugs. 1999 Jan;57(1):111-26. [PMID]

[41] Piraccini BM, Blume‐Peytavi U, Scarci F, Jansat JM, Falqués M, Otero R, Tamarit ML, Galván J, Tebbs V, Massana E, Topical Finasteride Study Group. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology. 2022 Feb;36(2):286-94. [PMID]

[42] Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA. A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women. Journal of drugs in dermatology: JDD. 2018 Apr 1;17(4):457. [PMID]

[43] Caserini M, Radicioni M, Leuratti C, Terragni E, Iorizzo M, Palmieri R. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. International journal of clinical pharmacology and therapeutics. 2016;54(1):19.[PMID]

[44] Kim S, Eum J, Yang H, Jung H. Transdermal finasteride delivery via powder-carrying microneedles with a diffusion enhancer to treat androgenetic alopecia. Journal of Controlled Release. 2019 Dec 28;316:1-1.[PMID]

[45] Khan MZ, Khan SA, Ubaid M, Shah A, Kousar R, Murtaza G. Finasteride topical delivery systems for androgenetic alopecia. Current drug delivery. 2018 Oct 1;15(8):1100-11.[PMID]

[46] Than JK, Rodriguez K, Khera M. Post-finasteride Syndrome: A Review of Current Literature. Current Sexual Health Reports. 2018 Sep;10(3):152-7.[LINK]

[47] Farkas HS, Jee YH, Szymczuk V, Leschek EW. Persistent gynecomastia due to Short-term Low-dose finasteride for androgenetic alopecia. JCEM Case Reports. 2024 May;2(5):luae050.[PMID]

[48] Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. The journal of sexual medicine. 2011 Jun;8(6):1747-53.. [LINK]

[49] Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. The Journal of clinical psychiatry. 2012 Aug 7;73(9):4275. [PMID]

[50] Irwig MS. Persistent sexual side effects of finasteride: could they be permanent?. The journal of sexual medicine. 2012 Nov;9(11):2927-32. [PMID]

[51] Traish AM. Post-finasteride syndrome: a surmountable challenge for clinicians. Fertility and sterility. 2020 Jan 1;113(1):21-50.[PMID]

[52] Noor NM, Abdul-Aziz A, Sheikh K, Somavarapu S, Taylor KM. In vitro performance of dutasteride-nanostructured lipid carriers coated with lauric acid-chitosan oligomer for dermal delivery. Pharmaceutics. 2020 Oct 20;12(10):994. [LINK]

[53] Oliveira PM, Alencar-Silva T, Pires FQ, Cunha-Filho M, Gratieri T, Carvalho JL, Gelfuso GM. Nanostructured lipid carriers loaded with an association of minoxidil and latanoprost for targeted topical therapy of alopecia. European Journal of Pharmaceutics and Biopharmaceutics. 2022 Mar 1;172:78-88.[PMID]

[54] Herz-Ruelas ME, Álvarez-Villalobos NA, Millán-Alanís JM, León-Gutiérrez HD, Ocampo-Garza SS, Gómez-Flores M, Grimalt R. Efficacy of intralesional and oral dutasteride in the treatment of androgenetic alopecia: a systematic review. Skin appendage disorders. 2020 Oct 9;6(6):338-45.[PMID]

[55] Xu XG, Chen HD. Prostanoids and hair follicles: implications for therapy of hair disorders. Acta Dermato-Venereologica. 2018;98(3):318-23. [PMID]

[56] Shin DW. The physiological and pharmacological roles of prostaglandins in hair growth. The Korean Journal of Physiology & Pharmacology: Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology. 2022 Nov 1;26(6):405-13.[PMID]

[57] Chovarda E, Sotiriou E, Lazaridou E, Vakirlis E, Ioannides D. The role of prostaglandins in androgenetic alopecia. International Journal of Dermatology. 2021 Jun;60(6):730-5.[PMID]

[58] Garza LA, Liu Y, Yang Z, Alagesan B, Lawson JA, Norberg SM, Loy DE, Zhao T, Blatt HB, Stanton DC, Carrasco L. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Science translational medicine. 2012 Mar 21;4(126):126ra34-.[PMID]

[59] Ahluwalia GS. Safety and efficacy of bimatoprost solution 0.03% topical application in patients with chemotherapy-induced eyelash loss. InJournal of Investigative Dermatology Symposium Proceedings 2013 Dec 1 (Vol. 16, No. 1, pp. S73-S76). Elsevier. [PMID]

[60] Subedi L, Pandey P, Shim JH, Kim KT, Cho SS, Koo KT, Kim BJ, Park JW. Preparation of topical bimatoprost with enhanced skin infiltration and in vivo hair regrowth efficacy in androgenic alopecia. Drug delivery. 2022 Dec 31;29(1):328-41.[PMID]

[61] Barrón-Hernández YL, Tosti A. Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia. Expert opinion on investigational drugs. 2017 Apr 3;26(4):515-22. [PMID]

[62] Uno H, Zimbric ML, Albert DM, Stjernschantz J. Effect of latanoprost on hair growth in the bald scalp of the stump-tailed macacque: a pilot study. Acta dermato-venereologica. 2002 Jan 1;82(1). [PMID]

[63] Razi-Khosroshahi MA, Sobhani SO, Yousefi KM, Harooni GH, Mashayekhi FA, Balasi JA, Goodarzi AZ. Latanoprost in treatment of alopecia areata and androgenic alopecia: A comprehensive review. Pakistan Journal of Medical and Health Sciences. 2021;17(4):1535.[LINK]

[64] Do Nascimento IJ, Harries M, Rocha VB, Thompson JY, Wong CH, Varkaneh HK, Guimarães NS, Arantes AJ, Marcolino MS. Effect of oral minoxidil for alopecia: systematic review. International journal of trichology. 2020 Jul 1;12(4):147-55.[PMID]

[65] Villani A, Fabbrocini G, Ocampo‐Candiani J, Ruggiero A, Ocampo‐Garza SS. Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose. Journal of the European Academy of Dermatology and Venereology. 2021 Jul;35(7):1485-92. [PMID]

[66] Feaster B, Onamusi T, Cooley JE, McMichael AJ. Oral minoxidil use in androgenetic alopecia and telogen effluvium. Archives of Dermatological Research. 2023 Mar;315(2):201-5.[PMID]

[67] Gomolin A, Litvinov IV, Netchiporouk E. Oral minoxidil: a possible new therapy for androgenetic alopecia. Journal of Cutaneous Medicine and Surgery. 2020 Jan;24(1):88-9.[PMID]

[68] Therianou A, Vincenzi C, Tosti A. How safe is prescribing oral minoxidil in patients allergic to topical minoxidil?. Journal of the American Academy of Dermatology. 2022 Feb 1;86(2):429-31.[PMID]

[69] Ramírez-Marín HA, Tosti A. Role of oral minoxidil in patterned hair loss. Indian dermatology online journal. 2022 Nov 1;13(6):729-33.[PMID]

[70] Randolph M, Tosti A. Oral minoxidil treatment for hair loss: a review of efficacy and safety. Journal of the American Academy of Dermatology. 2021 Mar 1;84(3):737-46.[PMID]

[71] Williams KN, Olukoga CT, Tosti A. Evaluation of the safety and effectiveness of oral minoxidil in children: a systematic review. Dermatology and therapy. 2024 Jul;14(7):1709-27.[PMID]

[72] Pallotti F, Senofonte G, Pelloni M, Cargnelutti F, Carlini T, Radicioni AF, Rossi A, Lenzi A, Paoli D, Lombardo F. Androgenetic alopecia: effects of oral finasteride on hormone profile, reproduction and sexual function. Endocrine. 2020 Jun;68(3):688-94.[PMID]

[73] Shapiro J, Kaufman KD. Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss). InJournal of Investigative Dermatology Symposium Proceedings 2003 Jun 1 (Vol. 8, No. 1, pp. 20-23). Elsevier.[PMID]

[74] Price VH, Menefee E, Sanchez M, Ruane P, Kaufman KD. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. Journal of the American Academy of Dermatology. 2002 Apr 1;46(4):517-23.[LINK]

[75] Laneuville P. CYCLOSPORIN A INDUCED REMISSION OF CD4+ T‐CLL ASSOCIATED WITH EOSINOPHILIA AND FASCIITIS. British journal of haematology. 1992 Feb;80(2):252-4. [PMID]

[76] Arif T, Dorjay K, Adil M, Sami M. Dutasteride in androgenetic alopecia: an update. Current clinical pharmacology. 2017 Feb 1;12(1):31-5.[PMID]

[77]Aleissa M. The efficacy and safety of oral spironolactone in the treatment of female pattern hair loss: a systematic review and meta-analysis. Cureus. 2023 Aug 16;15(8).[LINK]

[78]Burns LJ, De Souza B, Flynn E, Hagigeorges D, Senna MM. Spironolactone for treatment of female pattern hair loss. Journal of the American Academy of Dermatology. 2020 Jul 1;83(1):276-8. [PMID]

[79] Sadeghzadeh Bazargan, A., Tavana, Z., Dehghani, A., Jafarzadeh, A., Tabavar, A., Alavi Rad, E. and Goodarzi, A., 2024. The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral finasteride in women with androgenic alopecia, female and male hair loss patterns: a blinded randomized clinical trial. Journal of Cosmetic Dermatology, 23(2), pp.543-551. [LINK]

[80] Rathnayake D, Sinclair R. Use of spironolactone in dermatology. Skinmed. 2010;8(6):328–32; quiz 333.

[PMID]

[81] Alves R, Grimalt R. A review of platelet-rich plasma: history, biology, mechanism of action, and classification. Skin appendage disorders. 2018 Jan 16;4(1):18-24. [PMID]

[82] Abdin R, Zhang Y, Jimenez JJ. Treatment of androgenetic alopecia using PRP to target dysregulated mechanisms and pathways. Frontiers in medicine. 2022 Mar 16;9:843127. [PMID]

[83] Stevens J, Khetarpal S. Platelet-rich plasma for androgenetic alopecia: a review of the literature and proposed treatment protocol. International journal of women's dermatology. 2019 Feb 1;5(1):46-51.[PMID]

[84] Lynch MD, Bashir S. Applications of platelet-rich plasma in dermatology: a critical appraisal of the literature. Journal of Dermatological Treatment. 2016 May 3;27(3):285-9.[PMCID]

[85] Li ZJ, Choi HI, Choi DK, Sohn KC, Im M, Seo YJ, Lee YH, Lee JH, Lee Y. Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth. Dermatologic Surgery. 2012 Jul 1;38(7 pt1):1040-6. [PMID]

[86] Paichitrojjana A, Paichitrojjana A. Platelet rich plasma and its use in hair regrowth: a review. Drug design, development and therapy. 2023 Dec 31:635-45. [LINK]

[87] Mercuri SR, Paolino G, Di Nicola MR, Vollono L. Investigating the safety and efficacy of platelet-rich plasma (PRP) treatment for female androgenetic alopecia: review of the literature. Medicina. 2021 Mar 25;57(4):311.[PMID]

[88] Gressenberger P, Kopera D. Plättchenreiches Plasma (PRP) zur Behandlung der androgenetischen Alopezie (AGA): ein aktueller Literaturüberblick. Der Hautarzt. 2022 May;73(5):353-7. [PMID]

[89] Pillai JK, Mysore V. Role of low-level light therapy (LLLT) in androgenetic alopecia. Journal of Cutaneous and Aesthetic Surgery. 2021 Oct 1;14(4):385-91. [PMID]

[90] Satino JL, Markou M. Hair regrowth and increased hair tensile strength using the HairMax LaserComb for low-level laser therapy. International Journal of Cosmetic Surgery and Aesthetic Dermatology. 2003 Aug 1;5(2):113-7. [LINK]

[91] Frigo L, Luppi JS, Favero GM, Maria DA, Penna SC, Bjordal JM, Bensadoun RJ, Lopes-Martins RA. The effect of low-level laser irradiation (In-Ga-Al-AsP-660 nm) on melanoma in vitro and in vivo. BMC cancer. 2009 Nov 20;9(1):404.[PMID]

[92] Hou A, Cohen B, Haimovic A, Elbuluk N. Microneedling: a comprehensive review. Dermatologic Surgery. 2017 Mar 1;43(3):321-39. [PMID]

[93] Dhurat R, Sukesh MS, Avhad G, Dandale A, Pal A, Pund P. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. International journal of trichology. 2013 Jan 1;5(1):6-11.[PMID]

[94] Zhou Y, Jia L, Zhou D, Chen G, Fu Q, Li N. Advances in microneedles research based on promoting hair regrowth. Journal of Controlled Release. 2023 Jan 1;353:965-74.[PMID]

[95] Zhou Y, Seo J, Tu S, Nanmo A, Kageyama T, Fukuda J. Exosomes for hair growth and regeneration. Journal of bioscience and bioengineering. 2024 Jan 1;137(1):1-8.[PMID]

[96] Gupta AK, Renaud HJ, Halaas Y, Rapaport JA. Exosomes: a new effective non-surgical therapy for androgenetic alopecia?. Skinmed. 2020 Mar 1;18(2):96-100.[PMID]

[97] Buontempo MG, Alhanshali L, Ide M, Shapiro J, Lo Sicco K. Examining the Uncertainties Surrounding Exosome Therapy in Androgenetic Alopecia: A Call for Evidence-Based Practice. Journal of Drugs in Dermatology: JDD. 2024 Mar 1;23(3):e86-90.[PMID]

[98] Jimenez F, Alam M, Vogel JE, Avram M. Hair transplantation: basic overview. Journal of the American Academy of Dermatology. 2021 Oct 1;85(4):803-14. [PMID]

[99] Avram MR, Rogers NE. Hair transplantation for men. Journal of Cosmetic and Laser Therapy. 2008 Jan 1;10(3):154-60.[PMID]

[100] Kerure AS, Deshmukh N, Agrawal S. Challenges in hair transplantation practice as a beginner. Indian Journal of Dermatology, Venereology and Leprology. 2021 Mar 23;87(2):303-5.[PMID]

[101] Bunagan MK, Banka N, Shapiro J. Hair transplantation update: procedural techniques, innovations, and applications. Dermatologic clinics. 2013 Jan 1;31(1):141-53.[PMID]

[102] Avram MR, Finney R, Rogers N. Hair transplantation controversies. Dermatologic Surgery. 2017 Nov 1;43:S158-62.[PMID]

[103] Zhou Y, Chen C, Qu Q, Zhang C, Wang J, Fan Z, Miao Y, Hu Z. The effectiveness of combination therapies for androgenetic alopecia: a systematic review and meta‐analysis. Dermatologic therapy. 2020 Jul;33(4):e13741.[PMID]

[104] Abdi P, Awad C, Anthony MR, Farkouh C, Kenny B, Maibach HI, Ogunyemi B. Efficacy and safety of combinational therapy using topical minoxidil and microneedling for the treatment of androgenetic alopecia: a systematic review and meta-analysis. Archives of Dermatological Research. 2023 Dec;315(10):2775-85. [PMID]

[105] Ohyama M, Vogel JC. Gene delivery to the hair follicle. InJournal of Investigative Dermatology Symposium Proceedings 2003 Oct 1 (Vol. 8, No. 2, pp. 204-206). Elsevier.[PMID]

[106] Cotsarelis G. The hair follicle as a target for gene therapy. InAnnales de Dermatologie et de Venereologie 2002 May 1 (Vol. 129, No. 5 Pt 2, pp. 841-844).[LINK]

[107] Jandali S, Low DW. From surgery to pharmacology to gene therapy: the past, present, and future of hair restoration. Annals of plastic surgery. 2010 Oct 1;65(4):437-42.[PMID]